Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 3.81 is 61% above its 5-year average of 2.37, near the low end of its 5-year range (0.18–25.20).
As of the fiscal period ended Tuesday, June 30, 2026. 28.79% above its 12-month average of 2.96.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 3.81.
QUICK RATIO (ACID-TEST)
3.81
QUICK RATIO (ACID-TEST) AVG TTM
2.96
QUICK RATIO (ACID-TEST) AVG 3Y
2.29
QUICK RATIO (ACID-TEST) AVG 5Y
2.37
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+28.79%
CURRENT VS 3Y AVG
+66.36%
CURRENT VS 5Y AVG
+60.66%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
+13.82%
vs the sector median at left
Unicycive Therapeutics, Inc.
Market Cap
$111.35M
Quick Ratio (Acid-Test)
3.81
TTM Avg
2.96
3Y Avg
2.29
5Y Avg
2.37
Market Cap
$112.07M
Quick Ratio (Acid-Test)
6.49
TTM Avg
6.44
3Y Avg
8.52
5Y Avg
8.53
Market Cap
$110.43M
Quick Ratio (Acid-Test)
1.98
TTM Avg
1.40
3Y Avg
1.60
5Y Avg
1.70
Market Cap
$114.08M
Quick Ratio (Acid-Test)
11.47
TTM Avg
9.04
3Y Avg
10.96
5Y Avg
10.73
Market Cap
$108.55M
Quick Ratio (Acid-Test)
12.63
TTM Avg
12.83
3Y Avg
15.22
5Y Avg
15.22
Market Cap
$114.34M
Quick Ratio (Acid-Test)
2.39
TTM Avg
3.50
3Y Avg
2.69
5Y Avg
1.97
Market Cap
$108.23M
Quick Ratio (Acid-Test)
3.25
TTM Avg
3.06
3Y Avg
4.28
5Y Avg
3.23
Market Cap
$114.47M
Quick Ratio (Acid-Test)
13.40
TTM Avg
10.04
3Y Avg
7.53
5Y Avg
8.95
Market Cap
$114.56M
Quick Ratio (Acid-Test)
1.31
TTM Avg
1.18
3Y Avg
1.49
5Y Avg
3.22
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | $111.35M | 3.81 | 2.96 | 2.29 | 2.37 |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.07M | 6.49 | 6.44 | 8.52 | 8.53 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $110.43M | 1.98 | 1.40 | 1.60 | 1.70 |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | 11.47 | 9.04 | 10.96 | 10.73 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $108.55M | 12.63 | 12.83 | 15.22 | 15.22 |
| Genelux Corporation (GNLX)vs › | $114.34M | 2.39 | 3.50 | 2.69 | 1.97 |
| Vivani Medical, Inc. (VANI)vs › | $108.23M | 3.25 | 3.06 | 4.28 | 3.23 |
| Coya Therapeutics, Inc. (COYA)vs › | $114.47M | 13.40 | 10.04 | 7.53 | 8.95 |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.56M | 1.31 | 1.18 | 1.49 | 3.22 |
| Apyx Medical Corporation (APYX)vs › | $108.01M | 4.53 | 4.41 | 4.05 | 4.51 |
Quick Ratio
3.81
Excludes inventory
Current Ratio
3.81
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 3.81 |
| 2026-03-31 | 2.40 |
| 2025-12-31 | 2.59 |
| 2025-09-30 | 3.83 |
| 2025-06-30 | 2.18 |
| 2025-03-31 | 1.64 |
| 2024-12-31 | 1.28 |
| 2024-09-30 | 3.61 |
| 2024-06-30 | 3.37 |
| 2024-03-31 | 1.71 |
| 2023-12-31 | 0.76 |
| 2023-09-30 | 1.20 |
| 2023-06-30 | 1.42 |
| 2023-03-31 | 1.64 |
| 2022-12-31 | 0.81 |
| 2022-09-30 | 1.80 |
| 2022-06-30 | 4.43 |
| 2022-03-31 | 6.44 |
| 2021-12-31 | 8.75 |
| 2021-09-30 | 25.20 |
| 2021-06-30 | 0.18 |
| 2021-03-31 | 0.13 |
| 2020-12-31 | 0.07 |
| 2020-09-30 | 0.11 |
| 2020-06-30 | 0.02 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 0.02 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
